Pula General Hospital Ospedale Generale di Pola
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Pula General Hospital Ospedale Generale di Pola, investigators are evaluating a novel lipid‑lowering therapy to reduce the incidence of major adverse cardiovascular events in high‑risk patients as part of primary prevention efforts.
- Evaluation of inclisiran for ASCVD primary prevention
- Cardiovascular safety monitoring in immunotherapy combination trials
- Long‑term outcome assessment in patients with elevated cardiovascular risk
The department contributes several of the nine ongoing trials, with a team of seven investigators guiding the research.
Neoplasms
The oncology division is testing cutting‑edge immunotherapies and biosimilars to improve outcomes for individuals with metastatic non‑small cell lung cancer, focusing on response rates and safety profiles.
- Comparison of new checkpoint inhibitor combinations in NSCLC
- Biosimilar equivalence study with Keytruda (CT‑P51)
- Second‑line acasunlimab plus pembrolizumab versus standard docetaxel
- Fixed‑dose combination safety of tiragolumab and atezolizumab
Across the nine trials, lung cancer remains a central focus, leveraging the expertise of seven clinical investigators.
Nervous System Diseases
A dedicated study is examining a new agent for agitation in Alzheimer’s‑type dementia, aiming to provide a safer option that eases behavioral disturbances while maintaining tolerability.
- Safety and tolerability assessment of AVP‑786
- Behavioral outcome measures in dementia patients
- Quality‑of‑life impact evaluation for caregivers
This trial reflects the department’s commitment to improving neurological care alongside its oncology and cardiovascular programs.
Nutritional and Metabolic Diseases
Researchers are investigating an investigational compound that promotes weight loss and enhances glycemic control in adults with obesity and type 2 diabetes, with the goal of lowering cardiovascular risk.
- Effect of NNC0487‑0111 on body weight reduction
- Impact on glucose metabolism and HbA1c levels
- Safety and tolerability profile in overweight participants
These metabolic studies complement the cardiovascular prevention initiatives underway at the hospital.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Mabxience Research S.L.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pula General Hospital Ospedale Generale di Pola
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Study of Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 and Pembrolizumab in Advanced/Metastatic Non-Squamous NSCLC | Mabxience Research S.L. | Phase III | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2024-10-01 | 2025-02-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.